From September 4 to 5, 2026, the 8th CMC-CHINA themed "Reconstruction · Evolution" grandly opened at Suzhou International Expo Center. Bringing together pharmaceutical experts, enterprise leaders and industrial chain elites nationwide, the event focuses on the innovation and upgrading, intelligent manufacturing and high-quality development of the pharmaceutical sector. At this prestigious industry gathering, a number of authoritative rankings are unveiled. Biokin Pharmaceutical has been  simultaneously named to some lists including 2026 Top 101 Chinese Pharmaceutical Enterprises, 2026 Top 101 Innovative Chinese Pharmaceutical Enterprises, and 2026 Top 20 in New Drug BD Capability.

Hosted by Global Pharma Navigator, CMC-CHINA stands as a highly influential industrial summit within China’s pharmaceutical industry. Adopting multi-dimensional indicators including corporate R&D pipelines, clinical progress and industrialization capacity, the 2026 Top 101 Chinese Pharmaceutical Enterprises issued by CMC-CHINA, objectively reflects the development landscape of domestic innovative pharmaceutical companies and demonstrates the growing strength of China’s pharmaceutical industry.